New vaccine may help fight leukaemia: study

	Tweet

An experimental vaccine that boosts the immune system has produced good results in treating patients with chronic myeloid leukaemia (CML), Italian scientists said on Friday.

Treatment of the condition - a slow-progressing cancer in which too many white blood cells are made in the bone marrow - was revolutionised in 2001 with the approval of Novartis AG’s drug Glivec, which is sold as Gleevec in the United States. But that medicine does not eradicate the disease completely, and patients can develop resistance.

Monica Bocchia of the University of Siena and her colleagues found that a vaccine targeting a protein derived from a faulty chromosome, which is implicated in CML, improved the condition of patients significantly.

A group of 16 patients with stable disease, who were taking either Glivec or interferons, were given six vaccinations of the experimental vaccine. All but one showed an improvement, and seven reached complete cytogenetic remission, with no faulty chromosomes detected during cell division.

“Our preliminary data suggest that the addition of this vaccine to patients treated with conventional treatment might favour further reduction of the residual disease,” Bocchia reported in the Lancet medical journal.

Bocchia said her group was seeking funding for larger randomised clinical trials of the vaccine, which was developed by her scientific team rather than a commercial company.

Both Novartis and Bristol-Myers Squibb Co are working on experimental drugs aimed at patients with CML who no longer respond to treatment with Glivec. 

RELATED STORIES:
The first and only fusion inhibitor for the treatment of HIV   Pfizer provides opinion on European Lipitor patent   Outsourced heart study shows cheap drugs can help   Study supports controversial blood-thinning drug   FDA sends user-fee recommendations to Congress   Lilly stops pediatric trial of sepsis drug   US FDA clears Barr’s generic version of Allegra   Senators seek mandatory drug study database   Canada health panel says Vioxx pain drug safe enough   Glaxo Seeks Entry Into U.S. Flu Vaccine Mkt   U.S. group calls for safer asthma drug compounds   UK to save on generic medicines bill

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]